



## **Nexstim Receives System Order from Children's Hospital in United States**

*Press release, Helsinki, 1 July 2025 at 9 AM (EEST)*

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a new pediatric hospital customer in Southwestern United States.

The Nexstim NBS System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. An additional speech module, NexSpeech®, when used together with the NBS System 5, is indicated for non-invasive localization of cortical areas that do not contain essential speech function. The customer will mainly use their system for the preprocedural mapping of motor and speech areas of the brain. The data gained from the mapping can be used to evaluate risks, plan invasive procedures, and it can be integrated with surgical planning software to assist with invasive neuromonitoring in the operating room. This specific system also includes therapeutic capabilities that allow the system to be used for the treatment of major depressive disorder (MDD).

Mikko Karvinen, CEO of Nexstim, comments: *"It is important for us at Nexstim to be involved in making a difference in the lives of also very young patients. Creating a child-friendly environment for a mapping or treatment session with a Nexstim system is easy: for example, motor mapping can be done while children play with toys or sit in their caregiver's lap. We are happy to see pediatric hospitals choose our system that also offers opportunities for cross-departmental utilization."*

**Further information is available on the website [www.nexstim.com](http://www.nexstim.com), or by contacting:**

**Mikko Karvinen, CEO**

+358 50 326 4101

[mikko.karvinen@nexstim.com](mailto:mikko.karvinen@nexstim.com)

### **About Nexstim Plc**

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit [www.nexstim.com](http://www.nexstim.com)